UNLABELLED: The efficacy of specifically targeted anti-viral therapy for hepatitis C virus (HCV) (STAT-C), including HCV protease and polymerase inhibitors, is limited by the presence of drug-specific viral resistance mutations within the targeted proteins. Genetic diversity within these viral proteins also evolves under selective pressures provided by host human leukocyte antigen (HLA)-restricted immune responses, which may therefore influence STAT-C treatment response. Here, the prevalence ...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.
If you are the owner of this record, you can report an update to it here: Report update to this record